aflatoxin b1 has been researched along with Bile Duct Obstruction in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barton, CC; Barton, EX; Ganey, PE; Hill, DA; Roth, RA; Yee, SB | 1 |
| Ganey, PE; Luyendyk, JP; Roth, RA; Shores, KC | 1 |
2 other study(ies) available for aflatoxin b1 and Bile Duct Obstruction
| Article | Year |
|---|---|
Bacterial lipopolysaccharide exposure augments aflatoxin B(1)-induced liver injury.
Topics: 5'-Nucleotidase; Aflatoxin B1; Alanine Transaminase; Alkaline Phosphatase; Animals; Apoptosis; Aspartate Aminotransferases; Bile Acids and Salts; Chemical and Drug Induced Liver Injury; Cholestasis; Drug Synergism; Escherichia coli; gamma-Glutamyltransferase; In Situ Nick-End Labeling; Lipopolysaccharides; Liver; Male; Rats; Rats, Sprague-Dawley | 2000 |
Bacterial lipopolysaccharide exposure alters aflatoxin B(1) hepatotoxicity: benchmark dose analysis for markers of liver injury.
Topics: Aflatoxin B1; Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Benchmarking; Bile Ducts, Intrahepatic; Chemical and Drug Induced Liver Injury; Cholestasis; Dose-Response Relationship, Drug; Drug Synergism; Escherichia coli; Injections, Intraperitoneal; Lipopolysaccharides; Liver; Male; No-Observed-Adverse-Effect Level; Rats; Rats, Sprague-Dawley | 2002 |